Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

In an Untitled Letter, regulators said Facebook promotions for Pfizer’s lymphoma therapy overstated its approved use and ...

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...

Pfizer has filed a lawsuit against Metsera, Metsera’s board of directors and Novo Nordisk, claiming they breached a merger agreement. The lawsuit, filed in the U.S. District Court for the District of ...

Vaccine makers Pfizer PFE.N and BioNTech 22UAy.DE halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to ...